Conference Coverage

Genetic markers may help predict allogeneic SCT outcomes


 

REPORTING FROM THE 2018 BMT TANDEM MEETINGS


In the current study, haplotype 4 was only found to involve rs1718119 co-inherited with rs2230912, and was associated with substantially decreased relapse-free survival overall (hazard ratio, 0.6946), when compared with haplotype 2 (HR, 0.2078), he said.

The differences between haplotype 4 and haplotype 2, and between haplotype 4 and patients with neither haplotype, were highly statistically significant.

Relapse-free survival did not differ significantly between those with haplotype 2 and those with neither haplotype (HR, 0.7717). Similarly, overall survival was significantly poorer among those with haplotype 4 versus haplotype 2 or no haplotype (HR, 0.2812 and 0.2882, respectively), but no difference was seen in overall survival between those with haplotype 2 and those with no haplotype (HR, 1.003), he said.


P2X7 is a purinergic signaling receptor located at chromosome 12q24–a region associated with inflammatory disorders. It plays an important role in immunogenic cell death. It is expressed in all leukocytes, with the highest level of expression seen in monocyte lineage. Binding of its ligand – extracellular adenosine 5’-triphosphate – leads to activation of dendritic cells and release of IL1b leading to T cell recruitment and the production of memory T cells.

Pages

Recommended Reading

CAR T before transplant yields durable remission in B-cell malignancies
MDedge Hematology and Oncology
Xenon imaging could detect lung involvement after HSCT
MDedge Hematology and Oncology
Low microbiota diversity linked to poor survival after transplant
MDedge Hematology and Oncology
Ibrutinib preserves immune memory while fighting cGVHD
MDedge Hematology and Oncology
Posttransplant cyclophosphamide helped reduce GVHD rates
MDedge Hematology and Oncology
High engraftment with new umbilical transplant technique
MDedge Hematology and Oncology
Study: Stick with TMP-SMX for posttransplant PJP prophylaxis
MDedge Hematology and Oncology
Coming soon: CAR T-cell approvals in multiple myeloma
MDedge Hematology and Oncology
Reduced intensity conditioning doesn’t protect fertility
MDedge Hematology and Oncology
Study shows value of pretransplant assessment of function, endurance
MDedge Hematology and Oncology